Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete break­down

Paul Bion­di was nev­er afraid to bet big dur­ing his stint as busi­ness de­vel­op­ment chief at Bris­tol-My­ers Squibb. And while the gam­bles didn’t all pay out, by any means, his ros­ter of pacts il­lus­trates the broad am­bi­tions the phar­ma gi­ant has had over the last 5 years — capped by the $74 bil­lion Cel­gene buy­out.

On Thurs­day, we learned that Bion­di had ex­it­ed the com­pa­ny. And Chris Doko­ma­ji­lar at Deal­For­ma came up with the com­plete break­down on every buy­out, li­cens­ing pact and prod­uct pur­chase Bris­tol-My­ers forged dur­ing his tenure in charge of the BD team at one of the busiest com­pa­nies in bio­phar­ma.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER